Tirzepatide Weight Loss Timeline: Month-by-Month Results

Quick Answer: In clinical trials of FDA-approved tirzepatide, many participants began noticing reduced appetite within the first 1–2 weeks, with weight loss continuing gradually over roughly 72 weeks as the dose was escalated under medical supervision. On average, trial participants lost a substantial percentage of body weight over that period, but individual results vary widely and are not guaranteed. The figures below come from trials of FDA-approved tirzepatide products (Mounjaro and Zepbound), not from compounded tirzepatide.

Understanding what the research shows—and over what time frame—can help you set realistic expectations and have a more informed conversation with your clinician. This article breaks down the typical titration schedule used in trials, what participants reported across the study period, and the many factors that influence individual response.

Important Safety Information & Not-FDA-Approved Disclaimer

Compounded tirzepatide is not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. The efficacy and safety data described in this article come from clinical trials of FDA-approved tirzepatide products (Mounjaro® and Zepbound®) and should not be assumed to apply to compounded formulations. Compounded medications may be appropriate only for patients who have a clinical need that cannot be met by an FDA-approved product, as determined by a licensed clinician.

Boxed Warning — Risk of Thyroid C-Cell Tumors: In rodent studies, tirzepatide caused thyroid C-cell tumors. It is unknown whether tirzepatide causes such tumors, including medullary thyroid carcinoma (MTC), in humans. Tirzepatide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your clinician immediately if you notice a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.

Other serious risks may include:

• Gastrointestinal effects: nausea, vomiting, diarrhea, constipation, and abdominal pain are common, especially after dose increases, and can sometimes be severe or lead to dehydration.
• Pancreatitis: inflammation of the pancreas has been reported. Seek care for severe, persistent abdominal pain that may radiate to the back.
• Gallbladder disease: gallstones and gallbladder inflammation have occurred and may require surgery.
• Acute kidney injury: dehydration from GI side effects can worsen kidney function.
• Other risks: low blood sugar (especially with insulin or sulfonylureas), serious allergic reactions, vision changes in people with diabetic retinopathy, and gallbladder problems.

This is not a complete list of risks. This article is educational and is not medical advice. Discuss your full medical history with a licensed clinician before starting any medication.

The Titration Schedule (For Reference)

FDA-approved tirzepatide products use a gradual dose-escalation schedule to help reduce gastrointestinal side effects. The schedule below reflects the titration used for FDA-approved products for reference only. Your dose is determined by your clinician based on your response and tolerability—do not self-adjust your dose.

Timeframe (Reference)	Dose	Purpose
Weeks 1–4	2.5 mg weekly	Initiation — starting dose, not intended for weight loss on its own
Weeks 5–8	5 mg weekly	First maintenance dose option
Weeks 9–12	7.5 mg weekly	Clinician-determined escalation if tolerated
Weeks 13–16	10 mg weekly	Maintenance dose option
Weeks 17–20	12.5 mg weekly	Clinician-determined escalation if needed and tolerated
Week 21+	15 mg weekly	Maximum approved dose

Note: Not everyone escalates to the highest dose. Many patients remain at a lower maintenance dose. Dosing decisions, including whether and when to increase, are made by your clinician—never adjust your dose on your own.

For more on how tirzepatide works and its dual GIP/GLP-1 mechanism, see our complete guide to tirzepatide.

What Participants Reported Over Time

The descriptions below summarize patterns reported in clinical trials of FDA-approved tirzepatide and in published medical literature. They describe possible experiences—not promises. Your timeline, side effects, and degree of response may differ. None of the outcomes below are guaranteed, and they reflect FDA-approved products rather than compounded tirzepatide.

Early Weeks (Starting/Lower Doses)

• Some people notice reduced appetite or earlier fullness within the first one to two weeks.
• Reduced “food noise” (constant thinking about food) is commonly described.
• Mild, temporary nausea or other GI effects can occur, particularly in the days after a dose increase.
• Early weight changes, when they occur, are typically modest and partly reflect fluid shifts.

Middle Phase (Dose Escalation)

• As the dose is gradually increased under medical supervision, appetite effects may become more noticeable for some people.
• GI side effects may briefly recur after each dose step and often ease over days.
• Some participants report changes in clothing fit over time; the rate and degree vary widely.

Longer Term (Maintenance Dose)

• In trials, weight loss generally continued gradually over roughly 72 weeks before leveling off.
• Side effects were often more manageable once a stable maintenance dose was reached.
• Results plateaued at different points and different magnitudes for different participants.

For strategies to manage side effects, see our side effect management guide.

Clinical Trial Results: SURMOUNT Studies

The following figures come from the SURMOUNT clinical trials of FDA-approved tirzepatide. They describe average results across study populations over the full trial period. Individual results vary widely and are not guaranteed, and these data do not describe compounded tirzepatide.

SURMOUNT-1 Trial (72 weeks)

In SURMOUNT-1, adults with obesity or overweight (without type 2 diabetes) received once-weekly tirzepatide or placebo over 72 weeks:1

• 5 mg dose: approximately 15% average body weight reduction
• 10 mg dose: approximately 19.5% average body weight reduction
• 15 mg dose: approximately 20.9% average body weight reduction
• Placebo: approximately 3.1% average body weight reduction

Weight loss was progressive over the trial: reductions were already underway by around 3 months, with most loss occurring over the full ~72 weeks. These are trial averages of an FDA-approved product; your results may differ.

SURMOUNT-5 Trial (Head-to-Head With Semaglutide)

SURMOUNT-5 was a head-to-head trial comparing FDA-approved tirzepatide with FDA-approved semaglutide in adults with obesity or overweight without diabetes:2

• Tirzepatide (max tolerated dose): approximately 20.2% average body weight reduction
• Semaglutide (maximum tolerated dose): approximately 13.7% average body weight reduction

In that specific trial, the average percentage body-weight reduction was greater in the tirzepatide group than in the semaglutide group. This finding comes from one head-to-head study of FDA-approved products; it does not describe compounded medications, and individual results vary. It is not a guarantee that any individual will lose more weight on one medication than another.

For a fuller comparison, see tirzepatide vs semaglutide.

Factors That Affect Individual Response

Many factors influence how a person responds and over what time frame. Response is highly individual and cannot be predicted with precision.

Factors Associated With Greater or Faster Response

• Higher starting BMI
• Consistent medication adherence as directed by a clinician
• Regular physical activity, including resistance training
• Adequate protein intake and nutrient-dense eating
• Adequate sleep and managed stress

Factors Associated With Slower or Smaller Response

• Lower starting BMI
• Sedentary lifestyle
• Poor sleep quality and high chronic stress
• Certain metabolic conditions (for example, hypothyroidism, PCOS, insulin resistance)
• Certain medications (for example, steroids, some antidepressants, some antipsychotics)

Nutrition Considerations

Eating patterns can support overall health during treatment. General guidance many clinicians discuss includes:

• Protein: adequate daily protein to help preserve muscle mass
• Nutrient density: vegetables, fruits, whole grains, and lean proteins
• Adequate calories: avoid overly restrictive intake; discuss targets with your clinician
• Hydration: drink fluids regularly, especially if experiencing GI side effects
• Limit empty calories: minimize highly processed foods, sugary drinks, and alcohol

For more detail, see our diet guide for tirzepatide.

Weight Loss Plateaus

Common, Temporary Plateaus

Periods without weight change are common and can relate to:

• Fluid retention (hormonal fluctuations, sodium intake)
• Changes in body composition from increased activity
• Normal physiologic adjustment

What to do: stay consistent, prioritize protein and hydration, and discuss any concerns with your clinician rather than changing your dose on your own.

When to Contact Your Clinician

If weight stalls for several weeks, or if you have questions about your dose, contact your clinician. Any dose change is a clinical decision. Also reach out promptly if you experience persistent or severe side effects (see the Important Safety Information above).

For more, see our tirzepatide plateau guide.

Setting Realistic Expectations

Clinical trials of FDA-approved tirzepatide reported substantial average body-weight reductions over roughly 72 weeks, but the range across individuals was wide. Some participants lost considerably more than the average; others lost less. No outcome is guaranteed, and trial averages for FDA-approved products do not predict any individual’s result on any product, including compounded tirzepatide.

What Tirzepatide Is Not

• It is not a guarantee of any specific amount of weight loss.
• It is not a substitute for ongoing healthy eating and activity.
• It does not build muscle; resistance training and protein support that.
• Effects may not persist after stopping without sustainable lifestyle habits.

For more, see our guide on stopping tirzepatide and maintaining results.

Maintenance After Weight Loss

Obesity is often managed as a chronic condition. Many patients and clinicians discuss long-term plans, which may include:

• Continuing or adjusting medication based on clinical judgment
• Identifying a maintenance dose determined by your clinician
• Ongoing lifestyle habits established during active treatment
• Regular follow-up to monitor response and safety

How long someone stays on therapy is an individualized decision made with a clinician, weighing benefits, risks, response, and personal circumstances.

Frequently Asked Questions

How quickly does tirzepatide start working?

In clinical trials of FDA-approved tirzepatide, some participants noticed reduced appetite within the first one to two weeks. Timing varies from person to person, and appetite changes do not guarantee any particular amount of weight loss.

How much weight will I lose on tirzepatide?

No specific amount can be promised. In trials of FDA-approved tirzepatide, participants lost a substantial percentage of body weight on average over roughly 72 weeks, with a wide range across individuals. Your result may be higher or lower, and these figures reflect FDA-approved products, not compounded tirzepatide.

What does the clinical data show at around 3 months?

In trials of FDA-approved tirzepatide, weight loss was progressive: reductions were already underway by roughly 3 months, with most loss occurring over the full ~72 weeks. Individual results vary widely and are not guaranteed.

Is tirzepatide more effective than semaglutide?

In the SURMOUNT-5 head-to-head trial of FDA-approved products, the average percentage body-weight reduction was greater in the tirzepatide group (about 20.2%) than in the semaglutide group (about 13.7%).2 This is one trial of FDA-approved products; it does not describe compounded medications and does not guarantee any individual’s result.

Do you lose weight every week?

Not necessarily. Weight can fluctuate week to week due to fluid shifts and other factors. Longer-term trends are more meaningful than week-to-week changes. Discuss your progress with your clinician.

What if my weight loss seems slow?

Response varies widely. If you have concerns, contact your clinician. Do not increase your dose on your own—any dose change is a clinical decision.

What are the most important risks to know?

Tirzepatide carries a boxed warning regarding the risk of thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. Other serious risks may include pancreatitis, gallbladder disease, kidney injury (often related to dehydration from GI side effects), and low blood sugar. See the Important Safety Information above and review your full history with a clinician.

Is compounded tirzepatide FDA-approved?

No. Compounded tirzepatide is not FDA-approved, and the FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. The clinical data in this article come from FDA-approved tirzepatide products.

Talking With a Contour Health Clinician

Understanding the clinical data can help you have an informed conversation with a licensed clinician about whether a GLP-1/GIP medication may be appropriate for you. Treatment is individualized, and no outcome can be guaranteed.

At Contour Health, our program includes:

• Compounded tirzepatide (not FDA-approved) — see current pricing on our compounded tirzepatide page
• Oversight by licensed clinicians, with clinician-directed dosing
• Ongoing support and check-ins for questions about your treatment
• Supplies included where applicable
• Medication shipped to your door

See If You May Be a Candidate

Want to compare options? See tirzepatide vs semaglutide or learn about the dosing schedule.

---

References:

1. Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022;387:205–216. PMID: 35441470
2. Aronne LJ, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.” N Engl J Med. 2025. doi:10.1056/NEJMoa2416394. https://www.nejm.org/doi/abs/10.1056/NEJMoa2416394